Targets › RV0006
1 program from 1 company in 2 trials: 2 Phase 3; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: the race on RV0006, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Huashan Hospital | Bedaquiline ATP synthase inhibitor | RV0006 | Phase 3 | Multidrug Resistant Tuberculosis; Drug-resistant Tuberculosis | Dec 2026 |
Multidrug Resistant Tuberculosis (1) Drug-resistant Tuberculosis (1)
–
Huashan Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.